Zhao Shuai, Feng Pengya, Meng Wenbo, Jin Weilin, Li Xun, Li Xiangkai
Intersection Laboratory of Life Medicine, School of Life Sciences, Lanzhou University, Lanzhou, China.
Medical Frontier Innovation Research Center, Institute of Cancer Neuroscience, The First Hospital of Lanzhou University, The First Clinical Medical College of Lanzhou University, Lanzhou, China.
Front Med (Lausanne). 2022 Mar 3;9:811176. doi: 10.3389/fmed.2022.811176. eCollection 2022.
COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has gained global attention. SARS-CoV-2 identifies and invades human cells angiotensin-converting enzyme 2 receptors, which is highly expressed both in lung tissues and intestinal epithelial cells. The existence of the gut-lung axis in disease could be profoundly important for both disease etiology and treatment. Furthermore, several studies reported that infected patients suffer from gastrointestinal symptoms. The gut microbiota has a noteworthy effect on the intestinal barrier and affects many aspects of human health, including immunity, metabolism, and the prevention of several diseases. This review highlights the function of the gut microbiota in the host's immune response, providing a novel potential strategy through the use of probiotics, gut microbiota metabolites, and dietary products to enhance the gut microbiota as a target for COVID-19 prevention and treatment.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的新型冠状病毒肺炎（COVID-19）已引起全球关注。SARS-CoV-2识别并侵入人类细胞血管紧张素转换酶2受体，该受体在肺组织和肠上皮细胞中均高度表达。疾病中肠-肺轴的存在对于疾病病因和治疗可能都极为重要。此外，多项研究报告称，感染患者会出现胃肠道症状。肠道微生物群对肠道屏障有显著影响，并影响人类健康的许多方面，包括免疫、代谢以及多种疾病的预防。本综述强调了肠道微生物群在宿主免疫反应中的作用，通过使用益生菌、肠道微生物群代谢产物和膳食产品来增强肠道微生物群，为COVID-19的预防和治疗提供了一种新的潜在策略。
